Commons:Valued image candidates/Jardiance 10mg box, angle view.jpg

Jardiance 10mg box, angle view.jpg

**promoted**
Image
Nominated by	grendel\|khan on 2024-03-27 16:13 (UTC)
Scope	Nominated as the most valued image on Commons within the scope: Empagliflozin, 10mg box, angle view
Used in	Global usage
Review (criteria)	Comment Please note, there seems to be a copyright on the packaging. --Archaeodontosaurus (talk) 11:59, 28 March 2024 (UTC)[reply] Comment I think you mean a trademark (the circled 'R'); I've added a notice on the image page. grendel\|khan 16:13, 28 March 2024 (UTC)[reply] Comment This seems a copyvio per COM:PACKAGING --Tagooty (talk) 09:38, 30 March 2024 (UTC)[reply] Comment Does that mean that most pictures in Category:Pharmaceutical product packaging are in violation? See previous VIC nominations: Commons:Valued image candidates/12-08-18-tilidin-retard.jpg and Commons:Valued image candidates/Fetzima 1.jpg; consensus seems to be that this is just text on a box, and any logos here are either very subtle or are de minimis. Should there be clearer policy? grendel\|khan 12:36, 30 March 2024 (UTC)[reply] The VI examples cited above are from 2015 and 2017. A few months ago, I had promoted as QI someone's image of a similar box. The image was subsequently deleted as a packaging copyvio. I believe that "design" refers to the layout of the text, fonts, shapes, colours, etc., not only the logo. I'm not an expert in Commons copyright policies, let's hear views of @Archaeodontosaurus: and others. --Tagooty (talk) 14:01, 30 March 2024 (UTC)[reply] Question Where is the package designed? If it's from the U.S., it would be under COM:TOO US, but I'd be a lot less sure about COM:TOO France, and almost everything is over COM:TOO UK. -- Ikan Kekek (talk) 03:26, 31 March 2024 (UTC)[reply] Info @Ikan Kekek: This medicine seems to be from the United States of America as the company marketing this product seems to be fron the USA, according to the address on the box. --Contributers2020^{Talk to me here!} 12:52, 31 March 2024 (UTC)[reply] Then no problem, and we can simply consider whether it's best in scope. -- Ikan Kekek (talk) 14:19, 31 March 2024 (UTC)[reply] Support Best in scope and useful. Thanks to @Ikan Kekek: for the useful info on TOO. --Tagooty (talk) 03:26, 1 April 2024 (UTC)[reply] Glad to help! -- Ikan Kekek (talk) 09:09, 1 April 2024 (UTC)[reply] Result: 1 support, 0 oppose => promoted. Archaeodontosaurus (talk) 05:17, 3 April 2024 (UTC)[reply]